Search | Clinical Trials Finder

Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A, Untreated Adult Acute Myeloid Leukemia
Interventions: Autologous Bone Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Cytarabine, Daunorubicin Hydrochloride, Decitabine, Etoposide, Filgrastim, Laboratory Biomarker Analysis, Pharmacological Study; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 15 Years to 59 Years
Enrollment: 546 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 46
States / cities: San Francisco, California • Lewes, Delaware • Newark, Delaware + 35 more

Conditions: Acute Myeloid Leukemia
Interventions: Entospletinib, Daunorubicin, Cytarabine, Decitabine, Azacitidine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 14
States / cities: Los Angeles, California • Chicago, Illinois • Maywood, Illinois + 10 more

Conditions: Leukemia, Myelodysplastic Syndromes
Interventions: Filgrastim, Cyclosporine, Decitabine, Allogeneic Bone Marrow Transplantation, Peripheral Blood Stem Cell Transplantation; Biological · Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Up to 60 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2002
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Head and Neck Cancer, Head and Neck Neoplasms, Head and Neck Squamous Cell Carcinoma
Interventions: Decitabine, Nivolumab; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Recurrent Nasopharyngeal Undifferentiated Carcinoma, Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7, Stage IV Nasopharyngeal Undifferentiated Carcinoma AJCC v7
Interventions: Azacitidine, Laboratory Biomarker Analysis, Pharmacological Study, Vorinostat; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 21 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Solid Tumor
Interventions: Decitabine, Cedazuridine; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 2
States / cities: Los Angeles, California • Baltimore, Maryland

Conditions: Relapsed or Refractory Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)
Interventions: KRT-232, Cytarabine, Decitabine; Drug
Lead sponsor: Kartos Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 8
States / cities: Chicago, Illinois • Baltimore, Maryland • New York, New York + 3 more

Conditions: Beta Thalassemia
Interventions: 5-Azacytidine; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: Not listed
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Follicular T-Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions: Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Etoposide, Duvelisib, Oral azacitidine; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 96
States / cities: Little Rock, Arkansas • Duarte, California • La Jolla, California + 74 more

Conditions: Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Interventions: Azacitidine, Laboratory Biomarker Analysis, Pharmacological Study; Drug · Other
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Melanoma
Interventions: Decitabine, Pegylated Interferon Alpha-2b; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine, Decitabine and Cedazuridine, Filgrastim, Imaging Procedure, Lumbar Puncture; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 13
States / cities: Birmingham, Alabama • Aurora, Colorado • Atlanta, Georgia + 10 more

Conditions: Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Chronic Myelomonocytic Leukemia, IDH2 Gene Mutation, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions: Azacitidine, Enasidenib Mesylate; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions: Decitabine, Laboratory Biomarker Analysis, Pevonedistat, Pharmacological Study; Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Duarte, California

Conditions: Glioblastoma (GBM), Diffuse Midline Glioma (DMG), Astrocytoma, IDH-Mutant, Grade 4, Diffuse Hemispheric Glioma, H3 G34-Mutant, Gliosarcoma of Brain
Interventions: Nivolumab, Azacitidine (AZA), lumbar puncture, MRI Contrast; Drug · Procedure · Diagnostic Test
Lead sponsor: Andrew P. Groves; Other
Eligibility: 13 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Acute Myelogenous Leukemia
Interventions: Decitabine; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 70 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Lymphoma
Interventions: azacytidine, vorinostat; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: AML/MDS, CMML, Relapse, Refractory Acute Lymphoblastic Leukemia, Relapse Leukemia, Relapsed Adult AML
Interventions: LP-108, LP-108 and azacitidine; Drug
Lead sponsor: Newave Pharmaceutical Inc; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 4
States / cities: Ann Arbor, Michigan • Cincinnati, Ohio • Columbus, Ohio + 1 more

Conditions: Acute Myeloid Leukemia
Interventions: Azacitidine, Venetoclax, NK Cells; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Cleveland, Ohio • Houston, Texas

Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Secondary Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Refractory Secondary Acute Myeloid Leukemia
Interventions: Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Echocardiography Test, Punch Biopsy, Questionnaire Administration, Ruxolitinib, Venetoclax; Drug · Procedure · Other
Lead sponsor: Jennifer Saultz; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 3
States / cities: Columbus, Ohio • Portland, Oregon • Dallas, Texas

Conditions: Blasts More Than 20 Percent of Bone Marrow Nucleated Cells, Blasts More Than 20 Percent of Peripheral Blood White Cells, Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions: Decitabine, Laboratory Biomarker Analysis, Ruxolitinib Phosphate; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions: Decitabine plus Fludarabine and Busulfan; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 45 Years to 80 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Myelodysplastic Syndrome, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute
Interventions: Azacitidine, Pevonedistat; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 454 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 128
States / cities: Daphne, Alabama • Mobile, Alabama • Goodyear, Arizona + 94 more

Conditions: Acute Myeloid Leukemia
Interventions: combination therapy using decitabine and midostaurin; Drug
Lead sponsor: University of Kansas; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Kansas City, Kansas

Search by objective public record fields.

Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)

Decitabine and Peripheral Stem Cell Transplantation in Treating Patients Who Have Relapsed Following Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia

Decitabine and Nivolumab in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma

Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

5-Azacytidine and Phenylbutyrate to Treat Severe Thalassemia

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Azacitidine in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia

Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma

Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients

Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory Diffuse Large b Cell Lymphoma (DLBCL)

Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML

A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)

Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia

PRO#0118: Decitabine Plus Mini Flu-Bu

Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)

Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid Leukemia